Floatz logo

ubt251

Obesity Disorder

The United Bio-Technology (Hengqin) Co., Ltd.Phase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
89/ 100

Competitive context

574 Active assets in the Obesity Disorder cohort.

Asset / SponsorPhaseRating
vi-0521
VIVUS LLC
Phase 4BBB
Tirzepatide
Royal North Shore Hospital
Phase 4BBB
asc30
Ascletis Pharma (China) Co., Limited
Phase 2BBB
Phentermine
Russell McCulloh, MD
Phase 4BBB
Efsubaglutide Alfa
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BBB

View all 50 →

Same molecule, other indications

ubt251 is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
53 / 100
View asset →
chronic kidney diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →